Fig. 1From: Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4Scheme of the commercial 11C-synthesizer used for the radiosynthesis and purification of [11C]erlotinib (SPE: solid phase extraction; PCV: product collection vial)Back to article page